C Doehn

No ORCID on file · 1 paper in corpus
review 2000
Current opinion in molecular therapeutics

Abarelix (PPI-149) is a luteinizing hormone-releasing hormone (LHRH) receptor antagonist under development by Praecis, Amgen and Sanofi-Synthelabo for the potential treatment of prostate cancer, breast cancer and hormone-related disorders […